Compare NEOS S&P 500 High Income ETF (SPYI) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? NEOS S&P 500 High Income ETF trades at $54.02 (market cap $12.50B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 4.7× NEOS S&P 500 High Income ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 57 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SPYI | TAK | |
|---|---|---|
Market Cap | $12.50B | $58.74B |
Volume | 3,058,962 | 3,110,994 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $19.05 |
52-Week Low | $47.98 | $13.23 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $53.995, showing minimal daily movement with a slight 0.03% decline. The technical outlook is bullish based on moving averages, though oscillators remain neutral. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and potential risks to principal value from covered call strategies.
The outlook for SPYI centers on its income generation appeal amid market volatility, but investors should weigh the trade-off between high yields and potential capital erosion. Key risks include sequence risk in retirement portfolios and the cap on upside during strong bull markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
